An influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli.

ABSTRACT:

Background

The A/H1N1/2009 influenza pandemic made evident the need for faster and higher-yield methods for the production of influenza vaccines. Platforms based on virus culture in mammalian or insect cells are currently under investigation. Alternatively, expression of fragments of the hemagglutinin (HA) protein in prokaryotic systems can potentially be the most efficacious strategy for the manufacture of large quantities of influenza vaccine in a short period of time. Despite experimental evidence on the immunogenic potential of HA protein constructs expressed in bacteria, it is still generally accepted that glycosylation should be a requirement for vaccine efficacy.

Methodology/principal findings

We expressed the globular HA receptor binding domain, referred to here as H

SUBMITTER: Aguilar-Yanez JM 

PROVIDER: S-EPMC2908544 | biostudies-literature | 2010 Jul

REPOSITORIES: biostudies-literature